Holen Sie sich die Stockscreener-App
3.25
7.41%
-0.26
Vorhandelsmarkt:
3.28
0.03
+0.92%
Schlusskurs vom Vortag:
$3.51
Offen:
$3.48
24-Stunden-Volumen:
4.27M
Relative Volume:
1.38
Marktkapitalisierung:
$529.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-167.86M
KGV:
-1.417
EPS:
-2.2935
Netto-Cashflow:
$-132.31M
1W Leistung:
-14.02%
1M Leistung:
-21.69%
6M Leistung:
+27.45%
1J Leistung:
+49.08%
1-Tages-Spanne:
$3.21
$3.51
1-Wochen-Bereich:
$3.21
$3.93
52-Wochen-Spanne:
$1.26
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
3.25 | 572.32M | 0 | -167.86M | -132.31M | -2.2935 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases - Yahoo Finance
Jennison Associates LLC Increases Stake in Cabaletta Bio Inc - GuruFocus
Investors’ Stock Portfolio: Top 5 Penny Stocks To Buy - Insider Monkey
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
Jennison Associates (NASDAQ: CABA) holds 24.27M shares, 11.4% - Stock Titan
Cabaletta Bio reports phase 1/2 data for autoimmune therapy - Investing.com UK
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data By Investing.com - Investing.com South Africa
CABA: Cabaletta Bio Shares Positive Clinical Updates at EULAR 20 - GuruFocus
Cabaletta Bio Highlights Rese-cel Data and Pivotal Path - TipRanks
Jefferies reiterates Cabaletta Bio stock rating on autoimmune data - Investing.com
Cabaletta Bio reports phase 1/2 data for autoimmune therapy By Investing.com - Investing.com Canada
Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - The Manila Times
Cabaletta Bio Shares Tick Up Ahead of June Data Investors Await - Bez Kabli
CABA - Finviz
Cabaletta Bio (CABA) Climbs 2.7% as Biotech Stock Tests Key Resistance Near $4.14Low Risk Entry Stocks - thelegaladvocate.com
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
CABA Technical Analysis | Trend, Signals & Chart Patterns | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
CABA stock on track for best day in 6 months after positive early results from cell therapy trial - MSN
Cabaletta Reports Drug-Free Responses in CAR-T Study - MyChesCo
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - sharewise.com
Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Inc (CABA) Stock Price, Quote, News & History - Benzinga
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
CABA Maintains Rating by Wells Fargo -- Price Target Raised to $4.00 - GuruFocus
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $16 to $16 - Moomoo
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $3.61 - Moomoo
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo - Moomoo
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Key facts: Cabaletta Q1 $0.39 Adj Loss, $43.52M Net Loss; ASGCT Data - TradingView
CABA Shows Promising Results in New Clinical Data - GuruFocus
CABA: Cabaletta Bio Signs Major Supply Agreement and Reports Pro - GuruFocus
Cabaletta Bio 2026 Q1 10-Q Filing: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Cabaletta Bio Unveils Promising Preconditioning-Free Rese-cel CAR-T Data and Automated Manufacturing Advances at ASGCT 2026 Annual Meeting - Minichart
Cabaletta Bio Reports Promising 2026 Q1 Results: Rese-cel CAR-T Therapy Advances, New Data & $150M Financing Highlighted - Minichart
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune (CABA) - Seeking Alpha
Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Cabaletta Bio (CABA) Fairly Valued After Q1 2026? EPS -$0.39 - GuruFocus
Cabaletta Bio presents data on preconditioning-free rese-cel - Investing.com UK
Cabaletta Bio presents data on preconditioning-free rese-cel By Investing.com - Investing.com Nigeria
Cabaletta Bio Reports Encouraging RESET-PV Trial Data - TipRanks
Cabaletta Bio (NASDAQ: CABA) details Q1 loss and $150M financing - Stock Titan
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting - The Manila Times
Cabaletta Bio (NASDAQ: CABA) warns on going concern despite $141M cash raise - Stock Titan
Cabaletta Bio, Inc. 1Q 2026: Net loss $(43.5M), EPS $(0.39) — 10-Q Summary - TradingView
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cabaletta Bio Inc-Aktie (CABA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | President, Science & Tech. |
Jan 21 '26 |
Buy |
2.19 |
11,312 |
24,763 |
31,312 |
| Tomasello Shawn | Director |
Jan 21 '26 |
Buy |
2.21 |
22,725 |
50,322 |
22,725 |
| Gavel Steve | Chief Commercial Officer |
Jan 21 '26 |
Buy |
2.27 |
22,170 |
50,215 |
22,170 |
| Bollard Catherine | Director |
Jan 21 '26 |
Buy |
2.27 |
4,405 |
9,982 |
5,405 |
| Nichtberger Steven | President & CEO |
Jan 21 '26 |
Buy |
2.24 |
45,000 |
100,778 |
1,031,483 |
| Simon Mark | Director |
Jan 21 '26 |
Buy |
2.28 |
11,061 |
25,261 |
147,205 |
| Gerard Michael | General Counsel |
Jan 21 '26 |
Buy |
2.27 |
6,600 |
14,979 |
6,600 |
1.13%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):